Increasing doses of Eriomin® were tested (200, 400, and 800 mg/day), but the lowest dose of 200 mg/day was sufficient to achieve all critical benefits, such as an increase in GLP‐1, an improvement in the inflammatory condition and metabolic rate, and a reversal of hyperglycemia in 24% of treated patients (Ribeiro et al., 2019). Here, GCG is linked to Hyperglycemia.